If the economy doesn't rebound in the coming quarters, these three stocks might vaporize.
While still early in the season, signs point to decent reports.
Currency issues and a decline in U.S. demand hobble sales of the drug that accounts for 30% of pretax profits.
The company has a lot riding on this key drug.
Rather than focus on the group's poor earnings results, take note of booking trends.
Also, looking at the false dawn for natural gas stocks, and the hopes for U.S. companies in China.
ScanSource's warning may signal rough times for the industry.
Quarterly trends and balance sheets point the way toward the eventual survivors and also-rans.
Rising stock prices change the game for long and short strategies.
The stock is getting knocked down, but an FCC move could make the long-term picture bright.